Patent ID: 8618117
Filing Date: 2013-12-31
Classification: A61K,A61P,C07D

Abstract:
1. A method of inhibiting PDE9 in a mammal in need of such inhibition comprising the step of administering to the mammal PDE9-inhibiting amount of: a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: R (i) hydrogen, (ii) (C (iii) (C (iv) (C (v) (C (vi) (C (vii) (C (viii) 4 to 10 member heterocycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C (ix) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C (x) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C R R n is 1 or 2; A is —CR R (i) hydrogen, (ii) (C (iii) (C (iv) 4 to 10 member heterocycloalkyl, (v) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C (vi) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C (vii) LR R R R R b) a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle, carrier or diluent.